Cargando…

Identification of non-covalent SARS-CoV-2 main protease inhibitors by a virtual screen of commercially available drug-like compounds

[Figure: see text]

Detalles Bibliográficos
Autores principales:	Zhang, Linlin, Howland, McClane, Hilgenfeld, Rolf, Anderson, Marc O., Eagon, Scott
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier Ltd. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9759700/ https://www.ncbi.nlm.nih.gov/pubmed/33775840 http://dx.doi.org/10.1016/j.bmcl.2021.127990

Ejemplares similares

Virtual screening for small molecular non-covalent binders of the SARS-CoV-2 main protease
por: Lipiński, Piotr F.J., et al.
Publicado: (2021)

From Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease †
por: Göhl, Matthias, et al.
Publicado: (2022)

Evidence That VirS Is a Receptor for the Signaling Peptide of the Clostridium perfringens Agr-like Quorum Sensing System
por: Li, Jihong, et al.
Publicado: (2020)

Identification of a Dual Inhibitor of Secreted Phospholipase A(2) (GIIA sPLA(2)) and SARS-CoV-2 Main Protease
por: Theodoropoulou, Maria A., et al.
Publicado: (2022)

Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease
por: Zhu, Lili, et al.
Publicado: (2011)

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors
por: Zhang, Linlin, et al.
Publicado: (2020)

Erratum to: Liberation of SARS-CoV main protease from the viral polyprotein: N-terminal autocleavage does not depend on the mature dimerization mode
por: Chen, Shuai, et al.
Publicado: (2010)

In Silico Drug Repositioning to Target the SARS-CoV-2 Main Protease as Covalent Inhibitors Employing a Combined Structure-Based Virtual Screening Strategy of Pharmacophore Models and Covalent Docking
por: Vázquez-Mendoza, Luis Heriberto, et al.
Publicado: (2022)

Supercomputer simulation of the covalent inhibition of the main protease of SARS-CoV-2
por: Nemukhin, A. V., et al.
Publicado: (2022)

Hepatitis C virus NS3/4A inhibitors and other drug-like compounds as covalent binders of SARS-CoV-2 main protease
por: Andi, Babak, et al.
Publicado: (2022)

Structural and mutational analysis of the interaction between the Middle-East respiratory syndrome coronavirus (MERS-CoV) papain-like protease and human ubiquitin
por: Lei, Jian, et al.
Publicado: (2016)

Using More Than 1 (Path)Way to Kill a Host Cell: Lessons From Clostridium perfringens Enterotoxin
por: McClane, Bruce, et al.
Publicado: (2020)

Identification of non-covalent 3C-like protease inhibitors against severe acute respiratory syndrome coronavirus-2 via virtual screening of a Korean compound library
por: Lee, Joo-Youn, et al.
Publicado: (2021)

Selective covalent targeting of SARS-CoV-2 main protease by enantiopure chlorofluoroacetamide
por: Yamane, Daiki, et al.
Publicado: (2022)

A Novel Small Acid Soluble Protein Variant Is Important for Spore Resistance of Most Clostridium perfringens Food Poisoning Isolates
por: Li, Jihong, et al.
Publicado: (2008)

Use of Clostridium perfringens Enterotoxin and the Enterotoxin Receptor-Binding Domain (C-CPE) for Cancer Treatment: Opportunities and Challenges
por: Gao, Zhijian, et al.
Publicado: (2012)

Human Claudin-8 and -14 Are Receptors Capable of Conveying the Cytotoxic Effects of Clostridium perfringens Enterotoxin
por: Shrestha, Archana, et al.
Publicado: (2013)

NanH Is Produced by Sporulating Cultures of Clostridium perfringens Type F Food Poisoning Strains and Enhances the Cytotoxicity of C. perfringens Enterotoxin
por: Li, Jihong, et al.
Publicado: (2021)

Diastereomeric Resolution Yields Highly Potent Inhibitor of SARS-CoV-2 Main Protease
por: Cooper, Mark S., et al.
Publicado: (2022)

Design of Wide-Spectrum Inhibitors Targeting Coronavirus Main Proteases
por: Yang, Haitao, et al.
Publicado: (2005)

Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease
por: Kneller, Daniel W., et al.
Publicado: (2022)

Repurposing Halicin as a potent covalent inhibitor for the SARS-CoV-2 main protease
por: Yang, Kai S., et al.
Publicado: (2022)

Mechanistic investigation of SARS-CoV-2 main protease to accelerate design of covalent inhibitors
por: Kim, Hoshin, et al.
Publicado: (2022)

Alkyne as a Latent Warhead to Covalently Target SARS-CoV-2 Main Protease
por: Ngo, Chau, et al.
Publicado: (2023)

Galaxy workflows for fragment-based virtual screening: a case study on the SARS-CoV-2 main protease
por: Bray, Simon, et al.
Publicado: (2022)

H172Y mutation perturbs the S1 pocket and nirmatrelvir binding of SARS-CoV-2 main protease through a nonnative hydrogen bond
por: de Oliveira, Vinicius Martins, et al.
Publicado: (2022)

Correction: Design of Wide-Spectrum Inhibitors Targeting Coronavirus Main Proteases
por: Yang, Haitao, et al.
Publicado: (2005)

Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
por: Kandeel, Mahmoud, et al.
Publicado: (2020)

Virtual screening based on molecular docking of possible inhibitors of Covid-19 main protease
por: Marinho, Emanuelle Machado, et al.
Publicado: (2020)

Virtual screening of peptides with high affinity for SARS-CoV-2 main protease
por: Porto, William Farias
Publicado: (2021)

Reevaluation of whether a Functional Agr-like Quorum-Sensing System Is Necessary for Production of Wild-Type Levels of Epsilon-Toxin by Clostridium perfringens Type D Strains
por: Mehdizadeh Gohari, Iman, et al.
Publicado: (2022)

An Integrative Approach to Dissect the Drug Resistance Mechanism of the H172Y Mutation of SARS-CoV-2 Main Protease
por: Clayton, Joseph, et al.
Publicado: (2023)

Food phytochemicals, epigallocatechin gallate and myricetin, covalently bind to the active site of the coronavirus main protease in vitro
por: Kato, Yoji, et al.
Publicado: (2021)

Contribution of the catalytic dyad of SARS-CoV-2 main protease to binding covalent and noncovalent inhibitors
por: Kovalevsky, Andrey, et al.
Publicado: (2023)

Enterotoxigenic Clostridium perfringens: Detection and Identification
por: Miyamoto, Kazuaki, et al.
Publicado: (2012)

The Se–S Bond Formation in the Covalent Inhibition Mechanism of SARS-CoV-2 Main Protease by Ebselen-like Inhibitors: A Computational Study
por: Parise, Angela, et al.
Publicado: (2021)

Crystal structure of the papain-like protease of MERS coronavirus reveals unusual, potentially druggable active-site features
por: Lei, Jian, et al.
Publicado: (2014)

Binary-QSAR guided virtual screening of FDA approved drugs and compounds in clinical investigation against SARS-CoV-2 main protease
por: OKTAY, Lalehan, et al.
Publicado: (2021)

Repurposing Known Drugs as Covalent and Non-covalent Inhibitors of the SARS-CoV-2 Papain-Like Protease
por: Delre, Pietro, et al.
Publicado: (2020)

Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors
por: Jiménez-Alberto, Alicia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_scp1982o2o9601ak3diqp29bli